Showing results (91-100 of 481) with videos related to

Sort By:
Pageof 49
American Heart Journal|March 25, 2014
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trialMarc P Bonaca, Deepak L Bhatt, Eugene Braunwald, et al.
Clinical Chemistry|July 26, 2011
Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery diseaseMichelle L O'Donoghue, Ziad Mallat, David A Morrow, et al.
Journal of the American College of Cardiology|October 29, 2013
AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57)Nihar R Desai, Robert P Giugliano, Jing Zhou, et al.
The American Journal of Cardiology|January 31, 2007
Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)Marc P Bonaca, Stephen D Wiviott, Marc S Sabatine, et al.
Circulation|July 24, 2019
Impact of ADCY9 Genotype on Response to AnacetrapibJemma C Hopewell, Maysson Ibrahim, Michael Hill, et al.
European Journal of Heart Failure|February 19, 2019
Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trialBrian A Bergmark, Jacob A Udell, David A Morrow, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 23, 2010
Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22Marc P Bonaca, David A Morrow, Eugene Braunwald, et al.
Clinical Cardiology|March 23, 2013
Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data RegistryOwen Mogabgab, Stephen D Wiviott, Elliot M Antman, et al.
Journal of the American College of Cardiology|June 15, 2007
Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrelMarc S Sabatine, David A Morrow, Anthony Dalby, et al.
American Heart Journal|February 28, 2016
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialMarc S Sabatine, Robert P Giugliano, Anthony Keech, et al.
Pageof 49